Phase 3 Clinical Trials With Primary Completion Dates in March 2022

This is a list of Phase 3 trials with primary completion dates in March 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ABEOAbeona Therapeutics Inc.2022-03-01Phase 3NCT04227106Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
CDTXCidara Therapeutics, Inc.2022-03-01Phase 3NCT04368559Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
EBSEmergent BioSolutions Inc.2022-03-01Phase 3NCT05072080A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
HLUYYH. Lundbeck A/S2022-03-01Phase 3NCT03548584A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
PYPDPolyPid Ltd.2022-03-01Phase 3NCT04411199D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
SELBSelecta Biosciences, Inc.2022-03-01Phase 3NCT04513366A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
SYNHSyneos Health, Inc.2022-03-01Phase 3NCT02851797Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
ZEALZealand Pharma A/S2022-03-01Phase 3NCT03941236Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism